Literature DB >> 19458626

SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival.

U Mahlknecht, C-L Dransfeld, N Bulut, M Kramer, C Thiede, G Ehninger, M Schaich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19458626     DOI： 10.1038/leu.2009.113

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  17 in total

1.  Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

Authors:  Donald Lavelle; Kestis Vaitkus; Yonghua Ling; Maria A Ruiz; Reda Mahfouz; Kwok Peng Ng; Soledad Negrotto; Nicola Smith; Pramod Terse; Kory J Engelke; Joseph Covey; Kenneth K Chan; Joseph Desimone; Yogen Saunthararajah
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.

Authors:  Jun Amaki; Makoto Onizuka; Ken Ohmachi; Yasuyuki Aoyama; Ryujiro Hara; Akifumi Ichiki; Hidetsugu Kawai; Ai Sato; Mitsuki Miyamoto; Masako Toyosaki; Shinichiro Machida; Minoru Kojima; Yukari Shirasugi; Hiroshi Kawada; Yoshiaki Ogawa; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2015-03-04       Impact factor: 2.490

3.  Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer.

Authors:  Hamza Mameri; Ivan Bièche; Didier Meseure; Elisabetta Marangoni; Géraldine Buhagiar-Labarchède; André Nicolas; Sophie Vacher; Rosine Onclercq-Delic; Vinodh Rajapakse; Sudhir Varma; William C Reinhold; Yves Pommier; Mounira Amor-Guéret
Journal:  Clin Cancer Res       Date:  2016-09-06       Impact factor: 12.531

Review 4.  Genetic factors influencing cytarabine therapy.

Authors:  Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

Review 5.  The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.

Authors:  Ashkan Emadi; Judith E Karp
Journal:  Pharmacogenomics       Date:  2012-08       Impact factor: 2.533

6.  Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients.

Authors:  Abdelrahman H Elsayed; Xueyuan Cao; Kristine R Crews; Varsha Gandhi; William Plunkett; Jeffrey E Rubnitz; Raul C Ribeiro; Stanley B Pounds; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2018-08-08       Impact factor: 2.533

7.  Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia.

Authors:  C D Drenberg; S W Paugh; S B Pounds; L Shi; S J Orwick; L Li; S Hu; A A Gibson; R C Ribeiro; J E Rubnitz; W E Evans; A Sparreboom; S D Baker
Journal:  Clin Pharmacol Ther       Date:  2016-02-20       Impact factor: 6.875

8.  High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia.

Authors:  J H Song; S H Kweon; H-J Kim; T-H Lee; W-S Min; H-J Kim; Y-K Kim; S Y Hwang; T S Kim
Journal:  Br J Cancer       Date:  2012-05-24       Impact factor: 7.640

9.  Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.

Authors:  Aurora Medina-Sanson; Arturo Ramírez-Pacheco; Silvia Selene Moreno-Guerrero; Elisa María Dorantes-Acosta; Metzeri Sánchez-Preza; Alfonso Reyes-López
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

10.  RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.

Authors:  Ajay Abraham; Savitha Varatharajan; Sreeja Karathedath; Chepsy Philip; Kavitha M Lakshmi; Ashok Kumar Jayavelu; Ezhilpavai Mohanan; Nancy Beryl Janet; Vivi M Srivastava; Ramachandran V Shaji; Wei Zhang; Aby Abraham; Auro Viswabandya; Biju George; Mammen Chandy; Alok Srivastava; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Pharmacogenomics       Date:  2015-06-17       Impact factor: 2.533
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.